Mirati Therapeutics, Inc., a commercial stage biotechnology company, announced the Journal of Clinical Oncology published in a Rapid Communication data indicating adagrasib, a potent and selective...
Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca’s IMFINZI in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy...
